Company intelligence / Profile preview
Releviate Therapeutics
San Diego, California, United Statesreleviatetherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
RLVT‑903, a human monoclonal antibody targeting MMP‑9, has entered Phase I clinical trials for peripheral and diabetic neuropathies. The company’s approach offers a first-in-class alternative to opioids by directly inhibiting key enzymes implicated in chronic and acute neuropathic pain. Preclinical data support high specificity and reduced off-target effects compared to previous small-molecule inhibitors. No published late-stage results yet.
- Therapeutic areas
- EndocrinologyNeurology
- Modalities
- Human monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
University of California Riverside — exclusive license for core antibodies technology developed at UCR and Duke University.
Beyond the preview
Go deeper on Releviate Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Releviate Therapeutics.